Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman

Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center. In this episode, we covered: The importance of shared decision-making in CLL treatment. When to initiate treatment for newly diagnosed CLL patients. The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors. Key considerations in choosing the right BTK inhibitor and managing side effects. The relevance of minimal residual disease (MRD) in treatment duration. Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice. Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  #Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib #CLL2025 #BTKinhibitors #Venetoclax #MRDnegative #OncologyBrothers